Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: A hospital-based case-control study in China

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Jin, Yongtang ^a   Xu, Heyun ^b   zhang, Chunye ^a   Kong, Yunming ^c   Hou, Yong ^c   Xu, Yingchun ^d   Xue, Shaoli ^c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; CYTOCHROME P450 1A1; DEATH ASSOCIATED PROTEIN KINASE; DNA; GLUTATHIONE TRANSFERASE M1; PROTEIN P16; RETINOIC ACID RECEPTOR BETA; APOPTOSIS REGULATORY PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DEATH-ASSOCIATED PROTEIN KINASE; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE TRANSFERASE; P16 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINA; CIGARETTE SMOKING; CONTROLLED STUDY; DNA METHYLATION; DNA POLYMORPHISM; DOSE RESPONSE; FEMALE; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; INTERVIEW; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NULL ALLELE; POLYMERASE CHAIN REACTION; PROMOTER REGION; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; TREND STUDY; TUMOR SUPPRESSOR GENE; ADENOCARCINOMA; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; SMOKING; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; APOPTOSIS REGULATORY PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP1A1; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, RETINOIC ACID; RISK FACTORS; SMOKING; SURVIVAL RATE;

EID: 77955373775     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-422     Document Type: Article

References (28)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83:584-594. 10.4065/83.5.584, 2718421, 18452692.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008, 359:1367-1380. 10.1056/NEJMra0802714, 18815398.
3. Lee K, Kang D, Clapper ML, Ingelman-Sundberg M, Ono-Kihara M, Kiyohara C, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. Cancer Epidemiol Biomarkers Prev 2008, 17:1120-1126. 10.1158/1055-9965.EPI-07-2786, 18463401.
4. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008, 123:1-7. 10.1002/ijc.23605, 18425819.
5. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP gene, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev 2000, 9:3-28.
6. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis 2007, 28:507-518. 10.1093/carcin/bgl253, 17183062.
7. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002, 3:461-469. 10.1016/S1470-2045(02)00815-X, 12147432.
8. Adonis M, Martinez V, Marin P, Gil L. CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water. Xenobiotica 2005, 35:519-530. 10.1080/00498250500057310, 16012082.
9. Shi X, Zhou S, Wang Z, Zhou Z, Wang Z. CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis. Lung Cancer 2008, 59:155-163. 10.1016/j.lungcan.2007.08.004, 17900751.
10. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005, 11:6505-6511. 10.1158/1078-0432.CCR-05-0625, 16166426.
11. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005, 11:1219-1225. 10.1158/1078-0432.CCR-04-2363, 15709192.
12. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Research 2001, 61:249-255.
13. Doll R, Hill AB. A study the aetiology of cancinoma of the lung. Br Med J 1952, 2:1271-1286. 10.1136/bmj.2.4797.1271, 2022425, 12997741.
14. Yoshino I, Maehara Y. Impact of smoking status on the biological behavior of lung cancer. Surg Today 2007, 37:725-734. 10.1007/s00595-007-3516-6, 17713724.
15. Cornfield J, Haenszel W, Hammond EC, Lilienfeld AM, Shimkin MB, Wynder EL. Smoking and lung cancer: recent evidence and a discussion of some questions. Intern J Epidemiol 2009, 38:1175-1191.
16. Doll R, Peto R. Mortality in relation to smoking: 20 year's observations on male British doctors. Br Med J 1976, 2:1525-1536. 10.1136/bmj.2.6051.1525, 1690096, 1009386.
17. Mattson ME, Pollack ES, Cullen JW. what are the odds that smoking will kill you?. Am J Public Health 1987, 77:425-431. 10.2105/AJPH.77.4.425, 1646951, 3826460.
18. Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N, Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 1990, 263:131-133. 10.1016/0014-5793(90)80721-T, 1691986.
19. Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, et al. CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 2003, 104:650-657. 10.1002/ijc.10995, 12594823.
20. Houlston RS. Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Pre 1999, 8:675-682.
21. Vineis P, Veglia F, Anttila S, Benhamou S, Clapper ML, Dolzan V, et al. CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. Biomarkers 2004, 9:298-305. 10.1080/13547500400011070, 15764294.
22. Vineis P, Anttila S, Benhamou S, Spinola M, Hirvonen A, Kiyohara C, et al. Evidence of gene gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis 2007, 28:1902-1905. 10.1093/carcin/bgm039, 17307802.
23. Benhamou S, Lee WJ, Alexandrie AK, Boffetta P, Bouchardy C, Butkiewicz D, et al. Meta- and pooled analysis of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 2002, 23:1343-1350. 10.1093/carcin/23.8.1343, 12151353.
24. Butkiewicz D, Cole KJ, Phillips DH, Harris CC, Chorazy M. GSTM1, GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels. Eur J Cancer Prev 1999, 8:315-323. 10.1097/00008469-199908000-00008, 10493307.
25. Belinsky SA. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 2005, 26:1481-1487. 10.1093/carcin/bgi020, 15661809.
26. Zöchbauer-Müller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 2002, 7:451-457. 10.1634/theoncologist.7-5-451, 12401908.
27. Safar AM, Spencer H, Su X, Coffey M, Cooney CA, Ratnasinghe LD, et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005, 11:4400-4405. 10.1158/1078-0432.CCR-04-2378, 15958624.
28. Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the GSTM1, GSTP1 MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationchip with aberrant promoter methylation of the CDKN2A and RARβ genes. Cancer Genet Cytogenet 2005, 162:10-20. 10.1016/j.cancergencyto.2005.03.008, 16157195.